Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind comparison of donepezil 23 mg SR vs 10 mg IR in moderate to severe Alzheimer's disease
2006-004888-54Phase 3Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jun 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of donepezil in Alzheimer's disease (AD) (2 arms), sponsored by Eisai Co., Ltd. Primary endpoints: Change from baseline in Severe Impairment Battery (SIB), Change from baseline in CIBIC+ (Clinician's Interview-Based Impression of Change plus caregiver input) and 1 more. Started Jun 2007; status: completed.
02
Drugs
donepezil
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2006-004888-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004888-54.